VEGF has immunosuppressive activity in ovarian cancer17, and anti-VEGF therapies can normalize the structure of intra-tumoral blood vessels, which correlates with pathologic response, and also reprograms the tumor immune microenvironment18. This evidence concerns the gene VEGFA and neoplasm.